CEFAZOLIN FOR INJECTION POWDER FOR SOLUTION

देश: कनाडा

भाषा: अंग्रेज़ी

स्रोत: Health Canada

सक्रिय संघटक:

CEFAZOLIN (CEFAZOLIN SODIUM)

थमां उपलब्ध:

TEVA CANADA LIMITED

ए.टी.सी कोड:

J01DB04

INN (इंटरनेशनल नाम):

CEFAZOLIN

डोज़:

10G

फार्मास्यूटिकल फॉर्म:

POWDER FOR SOLUTION

रचना:

CEFAZOLIN (CEFAZOLIN SODIUM) 10G

प्रशासन का मार्ग:

INTRAVENOUS

पैकेज में यूनिट:

1

प्रिस्क्रिप्शन प्रकार:

Prescription

चिकित्सीय क्षेत्र:

FIRST GENERATION CEPHALOSPORINS

उत्पाद समीक्षा:

Active ingredient group (AIG) number: 0109442003; AHFS:

प्राधिकरण का दर्जा:

APPROVED

प्राधिकरण की तारीख:

2013-04-12

उत्पाद विशेषताएं

_Pr_
_CEFAZOLIN FOR INJECTION Product Monograph Page 1 of 21 _
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
PR
CEFAZOLIN FOR INJECTION
POWDER FOR SOLUTION, 500 MG, 1.0 G AND 10.0 G, CEFAZOLIN (AS CEFAZOLIN
SODIUM) PER VIAL
Intravenous, Intramuscular
USP
Antibiotic
Teva Canada Limited
Date of Initial Authorization:
30 Novopharm Court
January 19, 1995
Toronto, Ontario
M1B 2K9
Date of Revision:
Canada
MAR 15, 2024
www.tevacanada.com
Submission Control Number: 265641
_Pr_
_CEFAZOLIN FOR INJECTION (Cefazolin Sodium) Product Monograph Page 2
of 21 _
RECENT MAJOR LABEL CHANGES
7 WARNINGS AND PRECAUTIONS
11/2020
TABLE OF CONTENTS
SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF
AUTHORIZATION ARE NOT LISTED.
RECENT MAJOR LABEL CHANGES
.....................................................................................
2
TABLE OF CONTENTS
.............................................................................................................
2
PART I: HEALTH PROFESSIONAL INFORMATION
......................................................... 3
1 INDICATIONS
..........................................................................................................................
3
2 CONTRAINDICATIONS
.........................................................................................................
4
4
DOSAGE AND ADMINISTRATION
......................................................................................
4
4.2 Recommended Dose and Dosage Adjustment
......................................................................
4
4.3 Reconstitution
.......................................................................................................................
6
4.4 Administration
......................................................................................................................
8
5 OVERDOSAGE
.........................................................................................................................
8
6 DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKA